We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · June 30, 2020

Nivolumab Monotherapy Is Effective in Japanese mRCC Patients in a Real-World Setting

International Journal of Clinical Oncology

 

Additional Info

International Journal of Clinical Oncology
A Multicenter Retrospective Study of Nivolumab Monotherapy in Previously Treated Metastatic Renal Cell Carcinoma Patients: Interim Analysis of Japanese Real-World Data
Int. J. Clin. Oncol. 2020 Jun 09;[EPub Ahead of Print], N Hinata, J Yonese, S Masui, Y Nakai, S Shirotake, K Tatsugami, T Inamoto, M Nozawa, K Ueda, T Etsunaga, T Osawa, M Uemura, G Kimura, K Numakura, K Yamana, H Miyake, S Fukasawa, K Ochi, H Kaneko, H Uemura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading